Lower levels of a protein measured at birth is associated with an increased risk of developing schizophrenia as an adult

Schizophrenia is a severe psychiatric disease characterized by disorganized behavior, delusions and hallucinations. Sadly, there is no clear understanding of its cause.

Recently, the University of Missouri Department of Psychological Sciences introduced an addition to their field of research with the opening of the Brain Imaging Center (BIC). The BIC will allow MU researchers to conduct behavioral research on diseases that can have tremendous impact, including Parkinson's disease, autism, schizophrenia and other neurocognitive disorders using magnetic resonance imaging (MRI) technology.

A factor that helps optimize brain formation and function may also provide clues about whether patients suffering with schizophrenia are headed toward relapse, researchers say.

Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH).

The underdevelopment of a specific region in the brain may lead to schizophrenia in individuals. According to research published today in BioMed Central's open access journal Molecular Brain, dentate gyrus, which is located in the hippocampus in the brain and thought to be responsible for working memory and mood regulation, remained immature in an animal model of schizophrenia.

Researchers from the University of Newcastle are investigating a new way to help schizophrenia patients develop their communication and social skills.

Reporting this week in the Archives of General Psychiatry, researchers at the Johns Hopkins University School of Medicine have uncovered for the first time molecular circuitry associated with schizophrenia that links three previously known, yet unrelated proteins.

Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.

Researchers have long sought a factor that can trigger the brain's ability to learn – and perhaps recapture the "sponge-like" quality of childhood. In the August 8 issue of the journal Cell, neuroscientists at Children's Hospital Boston report that they've identified such a factor, a protein called Otx 2.

When combined with antipsychotic medications, the estrogen estradiol appears to be a useful treatment in women with schizophrenia, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

Researchers have spent decades probing the causes of depression, schizophrenia and insomnia in humans. But a new study may have uncovered key insights into the origins of these and other conditions by examining a most unlikely research subject: worms.